ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC "
Episode Synopsis
CME credits: 0.75
Valid until: 31-03-2026
Claim your CME credit at https://reachmd.com/programs/cme/tailoring-first-line-regimens-patient-centric-selection-in-metastatic-escc/33030/
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored. Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Valid until: 31-03-2026
Claim your CME credit at https://reachmd.com/programs/cme/tailoring-first-line-regimens-patient-centric-selection-in-metastatic-escc/33030/
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored. Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
More episodes of the podcast ReachMD CME
The Fifth Pillar? Closing the Gap in HFrEF
14/11/2025
MOA: CDH6-Targeted Antibody-Drug Conjugates
14/11/2025
In God we trust